The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...

AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)Findings in ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Theratechnologies (THTX) presented data highlighting the limitations of using body mass index alone in assessing cardiovascular risk in people ...